CAS 17902-23-7|5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione|5-FLUORO-1-(TETRAHYDRO-2-FURFURYL)URACIL|tegafur|Ftorafur|5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione|...

基本信息

化学结构

分子式

C₈H₉FN₂O₃

分子量

200.1670632

精确质量

200.05972038

电荷

InChI

InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)

InChIKey

WFWLQNSHRPWKFK-UHFFFAOYSA-N

Canonic Smiles

O=c1[nH]c(=O)n(cc1F)C1CCCO1

Isomeric Smiles

Fc1cn(C2CCCO2)c(=O)[nH]c1=O

计算属性

JChem

Acid pKa

7.678831

质子受体

质子供体

LogD (pH = 5.5)

0.020991746

LogD (pH = 7.4)

-0.1571928

Log P

0.023826538

摩尔折射率

44.5014

极化性

16.845354

极化表面积

58.64

可自由旋转的化学键

里宾斯基五规则

true

数据来源

名称和标识

IUPAC标准名

5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

别名

5-FLUORO-1-(TETRAHYDRO-2-FURFURYL)URACILFtorafur5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dioneTegafur5-Fluoro-1-(tetrahydro-2-furyl)uracilTegafur5-Fluoro-1-(tetrahydro-2-furyl)uracilFluaidTegafurCitofurFulaidNeberkFutrafulFentalFT 207FulfeelExonalFluorofur5-Fluoro-1-(tetrahydro-2'-furyl)uracil1-(2-Tetrahydrofuryl)-5-fluorouracilFurflucilFranroseSinoflurol5-Fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)-pyrimidinedioneCoparogin-Fluorafur

IUPAC传统名

tegafur 5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

名称和标识

数据登录号

PubChem SID

MDL号

CAS号

EC号

PubChem CID

数据登录号

化合物性质

产品相关信息

药理学性质

生物活性机理

Thymidylate synthetase inhibitor

RNA synthesis inhibitor

Fluorouracil prodrug

DNA synthesis inhibitor

化合物性质

分子相关蛋白质

暂无数据

点击上传数据

分子图谱

暂无数据

点击上传数据

描述信息

Sigma Aldrich

T7205

Biochem/physiol Actions
Tegafur is a pro-drug of 5-fluorouracil, an antimetabolite used as an antineoplastic agent. It has been used as adjuvant chemotherapy for curatively resected colorectal cancer therapy.

TRC

T013900

Used as an antineoplastic.

描述信息

参考文献

PubChem文献

数据源提供

• Buroker, T., et al.: Cancer, 44, 48 (1979)

• Au., J.L., et al.: Cancer Treat. Rep., 63, 343 (1979)

• Fujimoto, S., Drugs of Today (Barcelona), 1985, 21, 125, (rev, pharmacol)

• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 878

• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 502

• Loo, T.L. et al., Drug Metab. Rev., 1978, 8, 137, (metab, rev)

• Au, J. et al., Cancer Chemother. Pharmacol., 1981, 7, 55, (metab)

• Aldrich Library of 13C and 1H FT NMR Spectra, 1992, 3, 366A, (nmr)

• Aldrich Library of FT-IR Spectra, 1st edn., 1985, 2, 811D, (ir)

• Yamamoto, S. et al., Arzneim.-Forsch., 1981, 31, 1268, (pharmacol)

• Ozaki, S. et al., Chem. Pharm. Bull., 1986, 34, 150, (synth)

• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, FMB000; UNJ810

• Yasumoto, M. et al., J. Med. Chem., 1977, 20, 1592, (synth, resoln)

• Uchida, T. et al., Chem. Pharm. Bull., 1993, 41, 1632, (polymorphism)

• Nakai, Y. et al., Chem. Pharm. Bull., 1982, 30, 2629; 1986, 34, 1242, (cryst struct, bibl)

参考文献

生物活性

PubChem BioAssay

生物活性